N/A Completed N=36 Randomized Triple-blind Treatment

A Double Blind Clinical Trial of DCS for Food Anxiety

Anorexia and Bulimia Nervosa

Source: ClinicalTrials.gov NCT01996644 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2018

Primary outcomePrimary: Anxiety as Measured by the Subjective Units of Distress (Ranging From 1 to 100). — 52.395; 58.983 Units on a scale

Summary

This is a pilot study investigating if cycloserine (DCS; a learning enhancement medication) augments exposure therapy for food anxiety in patients with anorexia and bulimia nervosa. The investigators expect that (a) exposure therapy will reduce anxiety (b) anxiety will be reduced more in the DCS relative to placebo condition (c) participants in the DCS condition will have a greater increase in Body Mass Index.

Outcome Measures

Outcome	Result	p-value
PRIMARY Anxiety as Measured by the Subjective Units of Distress (Ranging From 1 to 100).	52.395; 58.983	—
PRIMARY Body Mass Index	.385; .095	.043 sig

Eligibility Criteria

Inclusion Criteria

Diagnosed with Anorexia Nervosa, Bulimia Nervosa, Eating Disorder Not Otherwise Specified

Exclusion Criteria

Pregnant or planning on becoming pregnant
Psychotic or Manic

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01996644). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.